Positron Emission Tomography in oncology: Present and future of PET and PET/CT

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 3, 2009, Pages 239-254

  Papathanassiou, Dimitri ^a,b   Bruna Muraille, Claire ^a,b   Liehn, Jean Claude ^a,b   Nguyen, Tan Dat ^a,b   Curé, Hervé ^a,b  

^a INSTITUT JEAN GODINOT   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Imaging; Oncology; PET; PET CT

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; CHOLINE C 11; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; FLUOROACETIC ACID F 18; FLUOROCHOLINE F 18; FLUORODEOXYARABINOFURANOSYL NUCLEOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F18; FLUOROETHYLTYROSINE F 18; FLUOROGALACTO RGD F18; FLUOROLIPOCORTIN 5 F 18; FLUOROMETHYLTYROSINE F 18; FLUOROURACIL F18; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; THYMIDINE C 11; UNCLASSIFIED DRUG;

BRAIN TUMOR; BREAST CANCER; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LYMPHOMA; MELANOMA; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RADIOACTIVITY; REVIEW; SARCOMA; THYROID CANCER; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; X RAY;

ANIMALS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 71549153831     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.10.006     Document Type: Review

References (149)

1. Zanzonico P. Positron emission tomography: a review of basic principles, scanner design and performance, and current systems. Semin Nucl Med 34 (2004) 87-111
2. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
3. Paquet N., Albert A., Foidart J., and Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45 (2004) 784-788
4. Coleman R.E. Is quantitation necessary for oncological PET studies?. Eur J Nucl Med Mol Imaging 29 (2002) 133-135
5. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45 (2004) 1431-1434
6. Keyes Jr. J.W. SUV: standard uptake or silly useless value?. J Nucl Med 36 (1995) 1836-1839
7. Zasadny K.R., and Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 189 (1993) 847-850
8. Mercer J.R. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. J Pharm Pharm Sci 10 (2007) 180-202
9. Blodgett T.M., Meltzer C.C., and Townsend D.W. PET/CT: form and function. Radiology 242 (2007) 360-385
10. Townsend D.W. Positron emission tomography/computed tomography. Semin Nucl Med 38 (2008) 152-166
11. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37 (2007) 400-419
12. 18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 275 (2000) 18489-18494
13. Warburg O., Posener K., and Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z 152 (1924) 309-344
14. Lindholm P., Minn H., Leskinen-Kallio S., Bergman J., Ruotsalainen U., and Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 34 (1993) 1-6
15. Townsend D.W., Beyer T., and Blodgett T.M. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 33 (2003) 193-204
16. Goerres G.W., Kamel E., Heidelberg T.N., Schwitter M.R., Burger C., and von Schulthess G.K. PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 29 (2002) 351-360
17. Papathanassiou D., Becker S., Amir R., Meneroux B., and Liehn J.C. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source. Eur J Nucl Med Mol Imaging 32 (2005) 1422-1428
18. Nehmeh S.A., Erdi Y.E., Pan T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31 (2004) 3179-3186
19. Dawood M., Lang N., Jiang X., and Schafers K.P. Lung motion correction on respiratory gated 3-D PET/CT images. IEEE Trans Med Imaging 25 (2006) 476-485
20. Kinahan P.E., Hasegawa B.H., and Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33 (2003) 166-179
21. Pfannenberg A.C., Aschoff P., Brechtel K., et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 36-44
22. Bourguet P. 2002 standards, options and recommendations for the use of [18F]-FDG (PET-FDG) in cancerology. Bull Cancer (2003) 90 Spec. No.: S1-109
23. 18F-FDG PET in oncology. J Nucl Med 49 (2008) 480-508
24. 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
25. Hicks R.J., Mac Manus M.P., and Seymour J.F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35 (2005) 165-175
26. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52 (2004) 19-32
27. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46 (2005) 958-963
28. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 35 (2005) 186-196
29. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91 (2006) 522-529
30. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
31. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
32. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., and Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285 (2001) 914-924
33. Fischer B.M., Mortensen J., and Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2 (2001) 659-666
34. Mac Manus M.P., and Hicks R.J. PET scanning in lung cancer: current status and future directions. Semin Surg Oncol 21 (2003) 149-155
35. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139 (2003) 879-892
36. Birim O., Kappetein A.P., Stijnen T., and Bogers A.J. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79 (2005) 375-382
37. Alongi F., Ragusa P., Montemaggi P., and Bona C.M. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumori 92 (2006) 327-333
38. Fischer B.M., and Mortensen J. The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration 73 (2006) 267-276
39. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 463-471
40. Hellwig D., Ukena D., Paulsen F., Bamberg M., and Kirsch C.M. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 55 (2001) 367-377
41. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., and Oyen W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 110 (2007) 1654-1664
42. Vermeersch H., Loose D., Ham H., Otte A., and Van de W.C. Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers. Eur J Nucl Med Mol Imaging 30 (2003) 1689-1700
43. 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med 35 (2005) 214-219
44. Facey K., Bradbury I., Laking G., and Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11 (2007) iii-267
45. Rusthoven K.E., Koshy M., and Paulino A.C. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 (2004) 2641-2649
46. Liu T., Xu W., Yan W.L., Ye M., Bai Y.R., and Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 85 (2007) 327-335
47. 18F-FDG PET in suspected recurrent head and neck cancer. Acta Otorrinolaringol Esp 59 (2008) 190-197
48. Isles M.G., McConkey C., and Mehanna H.M. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 33 (2008) 210-222
49. Delbeke D., and Martin W.H. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34 (2004) 209-223
50. Wiering B., Krabbe P.F., Jager G.J., Oyen W.J., and Ruers T.J. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 (2005) 2658-2670
51. Wiering B., Krabbe P.F., Dekker H.M., Oyen W.J., and Ruers T.J. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 14 (2007) 771-779
52. Bipat S., van Leeuwen M.S., Comans E.F., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237 (2005) 123-131
53. Esteves F.P., Schuster D.M., and Halkar R.K. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 36 (2006) 169-181
54. Huebner R.H., Park K.C., Shepherd J.E., et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41 (2000) 1177-1189
55. 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
56. van Vliet E.P., Heijenbrok-Kal M.H., Hunink M.G., Kuipers E.J., and Siersema P.D. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98 (2008) 547-557
57. Orlando L.A., Kulasingam S.L., and Matchar D.B. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 20 (2004) 1063-1070
58. Pakzad F., Groves A.M., and Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36 (2006) 248-256
59. Bourguet P. Standards, options and recommendations for the use of PET-FDG in cancerology. Results in digestive system neoplasms. Bull Cancer (2003) 90 Spec. No.: S56-66
60. Sun L., Wu H., and Guan Y.S. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 13 (2007) 2775-2783
61. Turlakow A., Yeung H.W., Salmon A.S., Macapinlac H.A., and Larson S.M. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44 (2003) 1407-1412
62. 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging 31 (2004) 1413-1420
63. 18F-FDG-PET/MDCT. Eur J Radiol (2008) 10.1016/j.ejrad.2007.11.032
64. De Gaetano A.M., Calcagni M.L., Rufini V., Valenza V., Giordano A., and Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging (2008) 10.1007/s00261-008-9405-7
65. Eubank W.B., and Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 (2005) 84-99
66. Sloka J.S., Hollett P.D., and Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit 13 (2007) RA37-RA46
67. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18 (2000) 3495-3502
68. Bos R., van Der Hoeven J.J., van Der W.E., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
69. Shie P., Cardarelli R., Brandon D., Erdman W., and Abdulrahim N. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33 (2008) 97-101
70. Isasi C.R., Moadel R.M., and Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90 (2005) 105-112
71. Gu P., Pan L.L., Wu S.Q., Sun L., and Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. Eur J Radiol 1 (2008) 10.1016/j.ejrad.2008.02.019
72. Havrilesky L.J., Kulasingam S.L., Matchar D.B., and Myers E.R. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97 (2005) 183-191
73. Yen T.C., and Lai C.H. Positron emission tomography in gynecologic cancer. Semin Nucl Med 36 (2006) 93-104
74. Bourguet P., Hitzel A., Houvenaeghel G., Vinatier D., and Bosquet L. 2005 monitoring report: use of positron emission tomography with fluorodeoxyglucose in the management of patients with breast cancer, ovarian cancer, and uterine cancer. Gynecol Obstet Fertil 34 (2006) 437-459
75. Jadvar H., and Conti P.S. The reproductive tract. Semin Nucl Med 34 (2004) 262-273
76. Fanti S., Nanni C., Ambrosini V., Gross M.D., Rubello D., and Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging 51 (2007) 260-271
77. Bouchelouche K., and Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol 20 (2008) 321-326
78. Jana S., and Blaufox M.D. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36 (2006) 51-72
79. Bourguet P., Planchamp F., Montravers F., et al. Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder. Bull Cancer 93 (2006) 1228-1232
80. Bouchelouche K., and Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 179 (2008) 34-45
81. Mantzarides M., Papathanassiou D., Bonardel G., Soret M., Gontier E., and Foehrenbach H. High-grade lymphoma of the bladder visualized on PET. Clin Nucl Med 30 (2005) 478-480
82. 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 47 (2006) 1803-1807
83. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48 (2007) 764-770
84. Powles T., Murray I., Brock C., Oliver T., and Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 (2007) 1511-1520
85. 18F]-FDG (PET-FDG in cancerology integral connection). Bull Cancer (2003) 90 Spec. No.: S5-17
86. Friedman K.P., and Wahl R.L. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 34 (2004) 242-253
87. Schwimmer J., Essner R., Patel A., et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 44 (2000) 153-167
88. Prichard R.S., Hill A.D., Skehan S.J., and O'Higgins N.J. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89 (2002) 389-396
89. 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 48 Suppl. 1 (2007) 58S-67S
90. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 3779-3786
91. Bourguet P. Standards, options and recommendations for the use of PET-FDG in cancerology. Results in sarcomas. Bull Cancer (2003) 90 Spec. No.: S96-102
92. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44 (2003) 717-724
93. Bastiaannet E., Groen H., Jager P.L., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30 (2004) 83-101
94. Seve P., Billotey C., Broussolle C., Dumontet C., and Mackey J.R. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109 (2007) 292-299
95. 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44 (2003) 1301-1314
96. Herholz K., Coope D., and Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 6 (2007) 711-724
97. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 48 (2007) 1468-1481
98. Talbot J.N., Kerrou K., Gault N., et al. PET and malignant cerebral tumors. Presse Med 35 (2006) 1347-1353
99. Chen W., and Silverman D.H. Advances in evaluation of primary brain tumors. Semin Nucl Med 38 (2008) 240-250
100. Kasamon Y.L., Jones R.J., and Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48 Suppl. 1 (2007) 19S-27S
101. Van den Abbeele A.D. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 13 Suppl. 2 (2008) 8-13
102. Boss D.S., Olmos R.V., Sinaasappel M., Beijnen J.H., and Schellens J.H. Application of PET/CT in the development of novel anticancer drugs. Oncologist 13 (2008) 25-38
103. Gregoire V., Haustermans K., Geets X., Roels S., and Lonneux M. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med 48 Suppl. 1 (2007) 68S-77S
104. Czernin J., len-Auerbach M., and Schelbert H.R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48 Suppl. 1 (2007) 78S-88S
105. Weber W.A., and Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference?. J Nucl Med 48 Suppl. 1 (2007) 36S-44S
106. 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med 48 Suppl. 1 (2007) 28S-35S
107. Ahn P.H., and Garg M.K. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med 38 (2008) 141-148
108. Vogel W.V., Oyen W.J., Barentsz J.O., Kaanders J.H., and Corstens F.H. PET/CT: panacea, redundancy, or something in between?. J Nucl Med 45 Suppl. 1 (2004) 15S-24S
109. Kuehl H., Veit P., Rosenbaum S.J., Bockisch A., and Antoch G. Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J Nucl Med 48 Suppl. 1 (2007) 45S-57S
110. Padhani A.R., Krohn K.A., Lewis J.S., and Alber M. Imaging oxygenation of human tumours. Eur Radiol 17 (2007) 861-872
111. Kwee S.A., DeGrado T.R., Talbot J.N., Gutman F., and Coel M.N. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 37 (2007) 420-428
112. 18F]fluorothymidine. Semin Nucl Med 37 (2007) 429-439
113. 18F]-fluoro-l-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med 37 (2007) 440-450
114. 18F-fluoromisonidazole. Semin Nucl Med 37 (2007) 451-461
115. 18F-Fluoroestradiol. Semin Nucl Med 37 (2007) 470-476
116. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 37 (2007) 462-469
117. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
118. Nehmeh S.A., and Erdi Y.E. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 38 (2008) 167-176
119. Wester H.J. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 13 (2007) 3470-3481
120. Guha C., Alfieri A., Blaufox M.D., and Kalnicki S. Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. Semin Nucl Med 38 (2008) 105-113
121. Schoder H., and Ong S.C. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med 38 (2008) 119-128
122. Kumar R., Dhanpathi H., Basu S., Rubello D., Fanti S., and Alavi A. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 52 (2008) 50-65
123. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., and Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
124. Foo S.S., Abbott D.F., Lawrentschuk N., and Scott A.M. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 6 (2004) 291-305
125. Belkacemi Y., Tsoutsou P., Magne N., Castadot P., and Azria D. Metabolic functional imaging for tumor radiosensitivity monitoring. Crit Rev Oncol Hematol 62 (2007) 227-239
126. Cai W., and Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49 Suppl. 2 (2008) 113S-128S
127. Lahorte C.M., Vanderheyden J.L., Steinmetz N., Van de W.C., Dierckx R.A., and Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 31 (2004) 887-919
128. Duatti A. In vivo imaging of oligonucleotides with nuclear tomography. Curr Drug Targets 5 (2004) 753-760
129. Herschman H.R. Noninvasive imaging of reporter gene expression in living subjects. Adv Cancer Res 92 (2004) 29-80
130. Herschman H.R. PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Crit Rev Oncol Hematol 51 (2004) 191-204
131. Schoder H., and Gonen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 48 Suppl. 1 (2007) 4S-18S
132. Tatsumi M., Nakamoto Y., Traughber B., Marshall L.T., Geschwind J.F., and Wahl R.L. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-d-glucose. Cancer Res 63 (2003) 6252-6257
133. Wang J., and Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 5 (2005) 1053-1075
134. Nanni C., Rubello D., and Fanti S. Role of small animal PET for molecular imaging in pre-clinical studies. Eur J Nucl Med Mol Imaging 34 (2007) 1819-1822
135. Chatziioannou A.F. Instrumentation for molecular imaging in preclinical research: micro-PET and micro-SPECT. Proc Am Thorac Soc 2 (2005) 533-611
136. Chatziioannou A.F. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 29 (2002) 98-114
137. McVeigh E.R. Emerging imaging techniques. Circ Res 98 (2006) 879-886
138. Myers R. The biological application of small animal PET imaging. Nucl Med Biol 28 (2001) 585-593
139. Tai Y.C., Ruangma A., Rowland D., et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46 (2005) 455-463
140. Kim J.S., Lee J.S., Im K.C., et al. Performance measurement of the microPET focus 120 scanner. J Nucl Med 48 (2007) 1527-1535
141. Guo W.Y., Lee J.J., Lin M.H., et al. Merging molecular and anatomical information: a feasibility study on rodents using microPET and MRI. Nucl Med Commun 28 (2007) 804-812
142. Liang H., Yang Y., Yang K., Wu Y., Boone J.M., and Cherry S.R. A microPET/CT system for in vivo small animal imaging. Phys Med Biol 52 (2007) 3881-3894
143. Chapman J.D., Schneider R.F., Urbain J.L., and Hanks G.E. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 11 (2001) 47-57
144. Schutze C., Bergmann R., Yaromina A., et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 83 (2007) 311-315
145. Dearling J.L., Flynn A.A., Sutcliffe-Goulden J., et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 45 (2004) 101-107
146. 18F-FDG small-animal PET. Nucl Med Commun 28 (2007) 647-652
147. Prenen H., Deroose C., Vermaelen P., et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26 (2006) 1247-1252
148. Yang H., Berger F., Tran C., Gambhir S.S., and Sawyers C.L. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate 55 (2003) 39-47
149. Lucas A.J., Hawkes R.C., Ansorge R.E., et al. Development of a combined microPET-MR system. Technol Cancer Res Treat 5 (2006) 337-341